Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Welcome and introduction

Date

10 Sep 2022

Session

GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Topics

Tumour Site

Ovarian Cancer

Presenters

Gilles Freyer

Authors

G. Freyer

Author affiliations

Lyon, Hôpital de la Croix-Rousse, 69317 - Lyon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

10 Sep 2022

State of the art: What are the most current data and updates to treatment guidelines for first-line maintenance in ovarian cancer

Presenter: Domenica Lorusso

Session: GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Resources:

Webcast

10 Sep 2022

The art of treatment selection: Importance and impact of early treatment planning

Presenter: Charlie Gourley

Session: GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Resources:

Webcast

10 Sep 2022

Articles of individualised treatment: How can we begin to individualise treatment using biomarkers and available therapies

Presenter: Gilles Freyer

Session: GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Resources:

Webcast

10 Sep 2022

Closing remarks

Presenter: Gilles Freyer

Session: GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Resources:

Webcast